Novel Lassa Fever Vaccine Candidate Launches Clinical Trial
A novel vaccine candidate against Lassa fever virus (LASV) has successfully launched a Phase I clinical trial supported by the Coalition for Epidemic Preparedness Innovations (CEPI). CEPI's ultimate goal, as part of its plan to minimize or even eliminate the risk of future epidemic and pandemic threats, is to produce a licensed Lassa vaccine for routine immunization. Although several LASV vaccine candidates are conducting studies, the U.S. FDA has not approved one as of August 31, 2022.
Source: precisionvaccinations.com
